Validation of autophagy biomarkers in AIS patients should therefore include CSF measurements (e.g., Beclin-1, LC3B) and their correlation with infarct volume and neurological recovery metrics such as NIHSS and mRS [175]. This evidence concerns the gene BECN1 and androgen insensitivity syndrome.